Published in Cancer Weekly, August 1st, 2006
According to researchers in the United States, "We are developing two fusion proteins consisting of a diphtheria toxin (DT) linked to either granulocyte macrophage colony stimulating factor (DT388 -GMCSF) or interleukin-3 (DT388 -IL3). In trials, patients with anti-DT IgG concentrations >2.5 mcg/mL had significantly lower concentrations of either fusion protein. DT389 -IL2 is currently FDA approved for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.